Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4055) 4055
Book Chapter (10) 10
Dissertation (10) 10
Publication (8) 8
Newsletter (6) 6
Web Resource (3) 3
Magazine Article (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Newspaper Article (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2465) 2465
science & technology (2079) 2079
life sciences & biomedicine (2001) 2001
piperacillin (1370) 1370
male (1321) 1321
penicillanic acid - analogs & derivatives (1277) 1277
female (1272) 1272
piperacillin - therapeutic use (1036) 1036
biological and medical sciences (969) 969
medical sciences (931) 931
middle aged (916) 916
piperacillin - pharmacology (905) 905
microbiology (866) 866
tazobactam (850) 850
microbial sensitivity tests (831) 831
adult (820) 820
infectious diseases (805) 805
pharmacology & pharmacy (791) 791
pharmacology. drug treatments (786) 786
antibiotics (757) 757
anti-bacterial agents - therapeutic use (746) 746
aged (717) 717
anti-bacterial agents - pharmacology (664) 664
antibiotics. antiinfectious agents. antiparasitic agents (662) 662
antibacterial agents (628) 628
piperacillin - administration & dosage (615) 615
penicillanic acid - therapeutic use (595) 595
penicillanic acid - pharmacology (441) 441
anti-bacterial agents - administration & dosage (403) 403
piperacillin-tazobactam (378) 378
pseudomonas aeruginosa - drug effects (378) 378
adolescent (360) 360
penicillanic acid - administration & dosage (358) 358
piperacillin - adverse effects (343) 343
drug resistance (332) 332
drug therapy, combination (316) 316
bacterial infections - drug therapy (315) 315
bacteria (314) 314
treatment outcome (313) 313
aged, 80 and over (289) 289
prospective studies (289) 289
piperacillin - pharmacokinetics (285) 285
polycyclic compounds (268) 268
animals (262) 262
meropenem (262) 262
infections (259) 259
beta-lactamase inhibitors (249) 249
patients (247) 247
hospitals (245) 245
antimicrobial agents (243) 243
research article (242) 242
child (241) 241
piperacillin/tazobactam (241) 241
imipenem (234) 234
retrospective studies (234) 234
pseudomonas aeruginosa (231) 231
escherichia coli - drug effects (230) 230
anti-bacterial agents - adverse effects (226) 226
vancomycin (217) 217
general & internal medicine (214) 214
penicillanic acid - adverse effects (214) 214
penicillins - pharmacology (213) 213
ceftazidime (208) 208
risk factors (206) 206
health aspects (202) 202
abridged index medicus (196) 196
pseudomonas infections - drug therapy (196) 196
analysis (194) 194
cefepime (191) 191
anti-bacterial agents - pharmacokinetics (188) 188
drug therapy, combination - therapeutic use (187) 187
ciprofloxacin (186) 186
bacteria - drug effects (181) 181
penicillins - therapeutic use (180) 180
biochemical phenomena, metabolism, and nutrition (179) 179
amikacin (177) 177
pathogens (174) 174
cephalosporins - pharmacology (173) 173
penicillanic acid - pharmacokinetics (172) 172
mortality (171) 171
pharmacokinetics (169) 169
drug combinations (165) 165
child, preschool (163) 163
e coli (162) 162
enterobacteriaceae - drug effects (162) 162
ceftazidime - pharmacology (159) 159
research (159) 159
immunology (158) 158
drug synergism (155) 155
drug resistance in microorganisms (153) 153
pediatrics (153) 153
pneumonia (153) 153
drug resistance, microbial (150) 150
drug therapy, combination - pharmacology (149) 149
gram-negative bacteria - drug effects (148) 148
bacterial infections and mycoses (147) 147
piperacillin - blood (145) 145
time factors (145) 145
drug resistance, bacterial (144) 144
infant (144) 144
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3651) 3651
Japanese (166) 166
French (111) 111
German (79) 79
Spanish (66) 66
Chinese (65) 65
Italian (59) 59
Portuguese (19) 19
Turkish (16) 16
Russian (11) 11
Polish (7) 7
Korean (6) 6
Czech (5) 5
Danish (3) 3
Dutch (3) 3
Hebrew (3) 3
Swedish (3) 3
Lithuanian (2) 2
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
by Harris, Patrick N. A and Tambyah, Paul A and Lye, David C and Mo, Yin and Lee, Tau H and Yilmaz, Mesut and Alenazi, Tamer H and Arabi, Yaseen and Falcone, Marco and Bassetti, Matteo and Righi, Elda and Rogers, Benjamin A and Kanj, Souha and Bhally, Hasan and Iredell, Jon and Mendelson, Marc and Boyles, Tom H and Looke, David and Miyakis, Spiros and Walls, Genevieve and Al Khamis, Mohammed and Zikri, Ahmed and Crowe, Amy and Ingram, Paul and Daneman, Nick and Griffin, Paul and Athan, Eugene and Lorenc, Penelope and Baker, Peter and Roberts, Leah and Beatson, Scott A and Peleg, Anton Y and Harris-Brown, Tiffany and Paterson, David L and Merino Trial Investigators and Australasian Soc Infect Dis Clinic and MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 09/2018, Volume 320, Issue 10, pp. 984 - 994
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Escherichia coli Infections - mortality | Klebsiella pneumoniae - drug effects | Escherichia coli - drug effects | Humans | Middle Aged | Drug Resistance, Bacterial | Bacteremia - mortality | Ceftriaxone - pharmacology | Male | Cause of Death | Anti-Bacterial Agents - therapeutic use | Penicillanic Acid - therapeutic use | Adult | Female | Anti-Bacterial Agents - adverse effects | Meropenem | Penicillanic Acid - adverse effects | Thienamycins - adverse effects | Penicillanic Acid - analogs & derivatives | Thienamycins - therapeutic use | Escherichia coli Infections - drug therapy | Klebsiella Infections - drug therapy | Piperacillin, Tazobactam Drug Combination | Bacteremia - drug therapy | Piperacillin - adverse effects | Klebsiella Infections - mortality | Aged | Anti-Bacterial Agents - pharmacology | Piperacillin - therapeutic use | Klebsiella | Bacterial infections | Intravenous administration | Mortality | Clinical trials | Piperacillin-tazobactam | Infections | Ceftriaxone | Drug resistance | Patients | Side effects | Tazobactam | Cephalosporins | E coli | Piperacillin | Drug therapy | Blood diseases | Blood culture | Carbapenems
Journal Article
Details down arrow
2. Full Text Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
by Lipman, Jeffrey and Dimopoulos, George and Dulhunty, Joel and Koulenti, Despoina and Martin, Claude and Montravers, Philippe and Wallis, Steven C and Roberts, Jason A and Paul, Sanjoy and De Crop, Luc and Spapen, Herbert and Wauters, Joost and Jorens, Philippe and Dapper, Ilse and Ruano, Laura and Afonso, Elsa and Alvarez-Lerma, Francisco and Fernández, Francisco and Feijoo, Neus and Bardolet, Neus and Rovira, Assumpta and Castillo, Carlos and Lopez, Maria Jesus and Fernandez, Jose Luis and Teja, Jose Luis and Ots, Elsa and Montejo, Juan Carlos and Catalan, Mercedes and Prieto, Isidro and Gonzalo, Gloria and Galvan, Beatriz and Blasco, Miguel Angel and Meyer, Estibaliz and Vidaur, Loreto and Sebastian, Rosa and Velasco, Maria del Mar Martin and Esperatti, Mariano and Dupont, Herve and Lasocki, Sigismond and Constantin, Jean Michel and Payen, Jean François and Jaber, Samir and Joannes-Boyau, Olivier and Ostermann, Marlies and McKenzie, Catherine and Berry, Willaim and Smith, John and Rubulotta, Francesca and Gordon, Anthony and Stotz, Martin and Templeton, Maie and Ebm, Claudia and Pettilä, Ville and Kouliatsis, Georgios and Anthopoulos, Georgios and Choutas, George and Rantis, Thanos and Karatzas, Stylianos and Balla, Margarita and Papanikolaou, Metaxia and Kyriakopoulou, Magdalini and Petrochilou, Kalomoira and Kompoti, Maria and Michalia, Martha and Clouva-Molyvdas, Fillis-Maria and Gkiokas, Georgios and Malliotakis, Polychronis and Lilitsis, Emmanouil and Koulouras, Vassilios and Kalogirou, Mihalis and Komnos, Apostolos and Chaintoutis, Christos and Arvaniti, Kostoula and Matamis, Dimitrios and Kydona, Christina and Gritsi-Gerogianni, Nikoleta and Soultati, Ioanna and Chytas, Ilias and Antoniadou, Eleni and Antipa, Elli and Koukoubani, Triantafyllia and Bekos, Vasileios and Spring, Anna and Nikolaou, Hara and Laskou, Maria and Strouvalis, Ioannis and Kapogiannis, Spyridon and Soldatou, Ourania and Villa, Gianluca and Giarratano, Antonio and Cortegiani, Andrea and Montalto, Francesca and Sandroni, Claudio and Montagnani, Luca and Urbino, Rosario and De Rosa, Francesco G and Afonso, Susana and Gonçalves-Pereira, João and Baptista, João Pedro and Özveren, Arife and DALI Study Grp and DALI Study Group
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 01/2016, Volume 71, Issue 1, pp. 196 - 207
Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Intensive Care Units | Prospective Studies | Thienamycins - administration & dosage | Blood Chemical Analysis | Humans | Middle Aged | Thienamycins - pharmacokinetics | Critical Illness | Piperacillin - pharmacokinetics | Male | Treatment Outcome | Microbial Sensitivity Tests | Piperacillin - administration & dosage | Anti-Bacterial Agents - pharmacokinetics | Penicillanic Acid - pharmacokinetics | Female | Aged | Infusions, Intravenous | Anti-Bacterial Agents - administration & dosage | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - administration & dosage | Intensive care | Pharmacology | Kinetics | Antibiotics | Patients | Clinical outcomes | Index Medicus | Life Sciences | Microbiology and Parasitology | Human health and pathology | Infectious diseases | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
by Watkins, Richard R and Deresinski, Stan
Clinical infectious diseases, ISSN 1058-4838, 12/2017, Volume 65, Issue 12, pp. 2137 - 2143
Sepsis | vancomycin | piperacillin/tazobactam | nephrotoxicity | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Piperacillin - toxicity | Vancomycin - administration & dosage | Kidney - drug effects | Kidney - pathology | Humans | Combined Modality Therapy - adverse effects | Piperacillin - administration & dosage | Piperacillin - adverse effects | Vancomycin - adverse effects | Anti-Bacterial Agents - therapeutic use | Sepsis - drug therapy | Drug Therapy, Combination - adverse effects | Vancomycin - toxicity | Vancomycin - therapeutic use | Kidney Diseases - chemically induced | Penicillanic Acid - therapeutic use | Anti-Bacterial Agents - adverse effects | Penicillanic Acid - toxicity | Anti-Bacterial Agents - toxicity | Penicillanic Acid - adverse effects | Anti-Bacterial Agents - administration & dosage | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - administration & dosage | Piperacillin - therapeutic use | Drugs | Usage | Care and treatment | Drug therapy, Combination | Health aspects | Mitigation | Therapy | Kidneys | Antibiotics | Tazobactam | Toxicity | Piperacillin | Risk reduction | Vancomycin | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Effect of meropenem-vaborbactam vs piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection the TANGO I randomized clinical trial
by Kaye, Keith S and Bhowmick, Tanaya and Metallidis, Symeon and Bleasdale, Susan C and Sagan, Olexiy S and Stus, Viktor and Vazquez, Jose and Zaitsev, Valerii and Bidair, Mohamed and Chorvat, Erik and Dragoescu, Petru Octavian and Fedosiuk, Elena and Horcajada, Juan P and Murta, Claudia and Sarychev, Yaroslav and Stoev, Ventsislav and Morgan, Elizabeth and Fusaro, Karen and Griffith, David and Lomovskaya, Olga and Alexander, Elizabeth L and Loutit, Jeffery and Dudley, Michael N and Giamarellos-Bourboulis, Evangelos J
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 02/2018, Volume 319, Issue 8, pp. 788 - 799
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Acute Disease | Thienamycins - administration & dosage | Humans | Middle Aged | Boronic Acids - adverse effects | Male | Urinary Tract Infections - drug therapy | Piperacillin - administration & dosage | Piperacillin - adverse effects | Intention to Treat Analysis | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Boronic Acids - administration & dosage | Pyelonephritis - drug therapy | Penicillanic Acid - adverse effects | Thienamycins - adverse effects | Anti-Bacterial Agents - administration & dosage | Drug Combinations | Penicillanic Acid - analogs & derivatives | Urine - microbiology | Penicillanic Acid - administration & dosage | Practice Guidelines as Topic | Levofloxacin | Intravenous administration | Therapeutic applications | Clinical trials | Piperacillin-tazobactam | Infections | β-Lactamase | Urinary tract | Criteria | Drug resistance | Patients | Urinary tract diseases | Side effects | Microorganisms | Tazobactam | Piperacillin | Pyelonephritis | Meropenem | Drug therapy
Journal Article
Details down arrow
5. Full Text The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections
by Tamma, Pranita D and Rodriguez-Baňo, Jesus
Clinical infectious diseases, ISSN 1058-4838, 04/2017, Volume 64, Issue 7, pp. 972 - 980
ESBLs | Piperacillin-tazobactam | Cefepime | Carbapenems | Cephamycins | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Cephamycins - therapeutic use | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Piperacillin - pharmacology | beta-Lactamases - genetics | Penicillanic Acid - therapeutic use | beta-Lactamases - metabolism | Cephalosporins - pharmacology | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - pharmacology | Piperacillin, Tazobactam Drug Combination | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Treatment Outcome | beta-Lactamase Inhibitors - pharmacology | Cephamycins - pharmacology | beta-Lactamase Inhibitors - therapeutic use | Enterobacteriaceae - drug effects | Anti-Bacterial Agents - pharmacology | Enterobacteriaceae Infections - drug therapy | Piperacillin - therapeutic use | beta-Lactam Resistance - drug effects | Index Medicus | cefepime | carbapenems | piperacillin-tazobactam | Invited | cephamycins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Too much of a good thing: A retrospective study of β-lactam concentration-toxicity relationships
by Imani, Sahand and Buscher, Hergen and Marriott, Debbie and Gentili, Sheridan and Sandaradura, Indy
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 10/2017, Volume 72, Issue 10, pp. 2891 - 2897
Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Neurotoxicity Syndromes - diagnosis | Anti-Bacterial Agents - blood | Piperacillin - blood | Humans | Middle Aged | Clostridium Infections - etiology | Male | Incidence | Microbial Sensitivity Tests | beta-Lactams - blood | Anti-Bacterial Agents - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Thienamycins - blood | Adult | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Thienamycins - adverse effects | Thienamycins - therapeutic use | Bacterial Infections - drug therapy | Floxacillin - adverse effects | Floxacillin - therapeutic use | Floxacillin - blood | Neurotoxicity Syndromes - etiology | Piperacillin - adverse effects | beta-Lactams - adverse effects | Aged | Drug Monitoring | beta-Lactams - therapeutic use | Cohort Studies | Piperacillin - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dose optimization of piperacillin/tazobactam in critically ill children
by De Cock, Pieter A.J.G and van Dijkman, Sven C and de Jaeger, Annick and Willems, Jef and Carlier, Mieke and Verstraete, Alain G and Delanghe, Joris R and Robays, Hugo and Walle, Johan Vande and Della Pasqua, Oscar E and De Paepe, Peter
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 07/2017, Volume 72, Issue 7, pp. 2002 - 2011
Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Anti-Bacterial Agents - blood | Piperacillin - blood | Prospective Studies | Humans | Child, Preschool | Critical Illness | Piperacillin - pharmacokinetics | Infant | Male | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Piperacillin - administration & dosage | Female | Child | Penicillanic Acid - analogs & derivatives | Penicillanic Acid - administration & dosage | Drug Administration Schedule | Bacterial Infections - drug therapy | Adolescent | Anti-Bacterial Agents - pharmacokinetics | Penicillanic Acid - pharmacokinetics | Infusions, Intravenous | Anti-Bacterial Agents - administration & dosage | Monte Carlo Method | Penicillanic Acid - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion
by Dhaese, S.A.M and Colin, P and Willems, H and Heffernan, A and Gadeyne, B and Van Vooren, S and Depuydt, P and Hoste, E and Stove, V and Verstraete, A.G and Lipman, J and Roberts, J.A and De Waele, J.J
International journal of antimicrobial agents, ISSN 0924-8579, 12/2019, Volume 54, Issue 6, pp. 741 - 749
Pharmacokinetics | Critically ill | Piperacillin | Saturation | POPULATION PHARMACOKINETIC ANALYSIS | QUANTIFICATION | BETA-LACTAM ANTIBIOTICS | INTERMITTENT | PHARMACODYNAMICS | BOLUS | TAZOBACTAM | NONLINEAR PHARMACOKINETICS | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Anti-Bacterial Agents - blood | Piperacillin - blood | Drug Administration Schedule | Area Under Curve | Humans | Middle Aged | Critical Illness | Piperacillin - pharmacokinetics | Male | Piperacillin - administration & dosage | Anti-Bacterial Agents - therapeutic use | Computer Simulation | Anti-Bacterial Agents - pharmacokinetics | Female | Aged | Anti-Bacterial Agents - administration & dosage | Piperacillin - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
by De Waele, Jan J and De Waele, Jan J and Carrette, S and Carrette, S and Carlier, M and Carlier, M and Stove, V and Stove, V and Boelens, J and Boelens, J and Claeys, G and Claeys, G and Leroux-Roels, I and Leroux-Roels, I and Hoste, E and